MIJ821 + Placebo + Ketamine
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Depressive Disorder, Treatment-Resistant
Conditions
Depressive Disorder, Treatment-Resistant
Trial Timeline
Feb 8, 2019 → Mar 23, 2020
NCT ID
NCT03756129About MIJ821 + Placebo + Ketamine
MIJ821 + Placebo + Ketamine is a phase 2 stage product being developed by Novartis for Depressive Disorder, Treatment-Resistant. The current trial status is completed. This product is registered under clinical trial identifier NCT03756129. Target conditions include Depressive Disorder, Treatment-Resistant.
What happened to similar drugs?
20 of 20 similar drugs in Depressive Disorder, Treatment-Resistant were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03756129 | Phase 2 | Completed |
Competing Products
20 competing products in Depressive Disorder, Treatment-Resistant
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| duloxetine | Eli Lilly | Pre-clinical | 26 |
| Duloxetine Hydrochloride | Eli Lilly | Pre-clinical | 26 |
| LY2216684 | Eli Lilly | Phase 1 | 29 |
| LY2216684 | Eli Lilly | Phase 1 | 29 |
| Duloxetine | Eli Lilly | Phase 3 | 40 |
| LY2216684 + Digoxin | Eli Lilly | Phase 1 | 29 |
| Duloxetine + Paroxetine | Eli Lilly | Phase 3 | 40 |
| Duloxetine + placebo | Eli Lilly | Phase 3 | 40 |
| LY2216684 + Placebo + Escitalopram | Eli Lilly | Phase 2 | 35 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| quetiapine extended release (XR) + Placebo | Astellas Pharma | Phase 2 | 35 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| Mirtazapine Tablets | Sun Pharmaceutical | Approved | 43 |
| Duloxetine Hydrochloride | Shionogi | Phase 3 | 32 |
| Duloxetine Hydrochloride + Placebo | Shionogi | Phase 3 | 40 |
| ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1 | Ono Pharmaceutical | Phase 2 | 35 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 39 |
| Pramipexole ER + Escitalopram | Cipla | Phase 2 | 42 |